MOLECULAR ASPECTS OF OMICRON, VACCINE DEVELOPMENT AND RECOMBINANT STRAIN XE: A REVIEW.

Akash, K; Sharma, A; Kumar, D; Singh, SK; Gupta, G; Chellappan, DK; Dua, K; Nagraik, R

MOLECULAR ASPECTS OF OMICRON, VACCINE DEVELOPMENT AND RECOMBINANT STRAIN XE: A REVIEW.

Akash, K Sharma, A Kumar, D Singh, SK Gupta, G Chellappan, DK Dua, K

Nagraik, R

Permalink

Publisher:: Wiley
Publication Type:: Journal Article
Citation:: J Med Virol, 2022
Issue Date:: 2022-06-15

Closed Access

	Filename	Description	Size
	Omnicorn_Recombinant strains_Journal of Medical Virology - 2022 - K - Molecular aspects of Omicron vaccine development and recombinant strain XE A.pdf	Published version	1.84 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Akash, K
dc.contributor.author	Sharma, A
dc.contributor.author	Kumar, D
dc.contributor.author	Singh, SK
dc.contributor.author	Gupta, G
dc.contributor.author	Chellappan, DK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Nagraik, R
dc.date.accessioned	2022-06-27T23:24:30Z
dc.date.available	2022-06-27T23:24:30Z
dc.date.issued	2022-06-15
dc.identifier.citation	J Med Virol, 2022
dc.identifier.issn	0146-6615
dc.identifier.issn	1096-9071
dc.identifier.uri	http://hdl.handle.net/10453/158413
dc.description.abstract	The global pandemic of COVID-19 began in December 2019 and is still continuing. The past 2 years have seen the emergence of several variants that were more vicious than each other. The emergence of Omicron (B.1.1.529) proved to be a huge epidemiological concern as the rate of infection of this particular strain was enormous. The strain was identified in South Africa on November 24, 2021 and was classified as a 'Variant of Concern' on November 26, 2021. The Omicron variant possessed mutations in the key RBD region, the S region, thereby increasing the affinity of ACE2 for better transmission of the virus. Antibody resistance was found in this variant and it was able to reduce vaccine efficiency of vaccines. The need for a booster vaccine was brought forth due to the prevalence of the Omicron variant and, subsequently, this led to targeted research and development of variant-specific vaccines and booster dosage. This review discusses broadly the genomic characters and features of Omicron along with its specific mutations, evolution, antibody resistance, and evasion, utilization of CRISPR-Cas12a assay for Omicron detection, T-cell immunity elicited by vaccines against Omicron, and strategies to decrease Omicron infection along with COVID-19 and it also discusses on XE recombinant variant and on infectivity of BA.2 subvariant of Omicron. This article is protected by copyright. All rights reserved.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Wiley
dc.relation.ispartof	J Med Virol
dc.relation.isbasedon	10.1002/jmv.27936
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0605 Microbiology, 1108 Medical Microbiology
dc.subject.classification	Virology
dc.title	MOLECULAR ASPECTS OF OMICRON, VACCINE DEVELOPMENT AND RECOMBINANT STRAIN XE: A REVIEW.
dc.type	Journal Article
utslib.location.activity	United States
utslib.for	0605 Microbiology
utslib.for	1108 Medical Microbiology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2022-06-27T23:24:28Z
pubs.publication-status	Published online

Abstract:

The global pandemic of COVID-19 began in December 2019 and is still continuing. The past 2 years have seen the emergence of several variants that were more vicious than each other. The emergence of Omicron (B.1.1.529) proved to be a huge epidemiological concern as the rate of infection of this particular strain was enormous. The strain was identified in South Africa on November 24, 2021 and was classified as a 'Variant of Concern' on November 26, 2021. The Omicron variant possessed mutations in the key RBD region, the S region, thereby increasing the affinity of ACE2 for better transmission of the virus. Antibody resistance was found in this variant and it was able to reduce vaccine efficiency of vaccines. The need for a booster vaccine was brought forth due to the prevalence of the Omicron variant and, subsequently, this led to targeted research and development of variant-specific vaccines and booster dosage. This review discusses broadly the genomic characters and features of Omicron along with its specific mutations, evolution, antibody resistance, and evasion, utilization of CRISPR-Cas12a assay for Omicron detection, T-cell immunity elicited by vaccines against Omicron, and strategies to decrease Omicron infection along with COVID-19 and it also discusses on XE recombinant variant and on infectivity of BA.2 subvariant of Omicron. This article is protected by copyright. All rights reserved.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/158413